Neovacs SA (France) Performance
| ALNEV Stock | EUR 0.0002 0.00 0.00% |
The company secures a Beta (Market Risk) of -2.9, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Neovacs SA are expected to decrease by larger amounts. On the other hand, during market turmoil, Neovacs SA is expected to outperform it. At this point, Neovacs SA has a negative expected return of -1.31%. Please make sure to verify Neovacs SA's information ratio, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Neovacs SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Neovacs SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 10.1 M | |
| Total Cashflows From Investing Activities | -18.8 M |
Neovacs |
Neovacs SA Relative Risk vs. Return Landscape
If you would invest 0.14 in Neovacs SA on August 24, 2024 and sell it today you would lose (0.12) from holding Neovacs SA or give up 85.71% of portfolio value over 90 days. Neovacs SA is generating negative expected returns and assumes 18.113% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Neovacs on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Neovacs SA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neovacs SA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neovacs SA, and traders can use it to determine the average amount a Neovacs SA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0722
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALNEV |
Estimated Market Risk
| 18.11 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neovacs SA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neovacs SA by adding Neovacs SA to a well-diversified portfolio.
Neovacs SA Fundamentals Growth
Neovacs Stock prices reflect investors' perceptions of the future prospects and financial health of Neovacs SA, and Neovacs SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neovacs Stock performance.
| Return On Equity | -0.27 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (620.28) % | |||
| Current Valuation | (30.4 M) | |||
| Shares Outstanding | 590.99 M | |||
| Price To Earning | (1.94) X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 24.75 X | |||
| Revenue | 22.59 K | |||
| EBITDA | (12.49 M) | |||
| Cash And Equivalents | 1.42 M | |||
| Cash Per Share | 0.01 X | |||
| Debt To Equity | 2.60 % | |||
| Book Value Per Share | 3.30 X | |||
| Cash Flow From Operations | (9.91 M) | |||
| Earnings Per Share | 2.27 X | |||
| Total Asset | 48.55 M | |||
| Retained Earnings | (76 M) | |||
| Current Asset | 13 M | |||
| Current Liabilities | 5 M | |||
About Neovacs SA Performance
Assessing Neovacs SA's fundamental ratios provides investors with valuable insights into Neovacs SA's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Neovacs SA is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. Neovacs S.A. was founded in 1993 and is based in Paris, France. NEOVACS operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 24 people.Things to note about Neovacs SA performance evaluation
Checking the ongoing alerts about Neovacs SA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neovacs SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neovacs SA generated a negative expected return over the last 90 days | |
| Neovacs SA has high historical volatility and very poor performance | |
| Neovacs SA has some characteristics of a very speculative penny stock | |
| Neovacs SA has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.59 K. Net Loss for the year was (11.84 M) with loss before overhead, payroll, taxes, and interest of (4.54 M). | |
| Neovacs SA has accumulated about 1.42 M in cash with (9.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Neovacs SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neovacs SA's stock is overvalued or undervalued compared to its peers.
- Examining Neovacs SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neovacs SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neovacs SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neovacs SA's stock. These opinions can provide insight into Neovacs SA's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Neovacs Stock Analysis
When running Neovacs SA's price analysis, check to measure Neovacs SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neovacs SA is operating at the current time. Most of Neovacs SA's value examination focuses on studying past and present price action to predict the probability of Neovacs SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neovacs SA's price. Additionally, you may evaluate how the addition of Neovacs SA to your portfolios can decrease your overall portfolio volatility.